Clinical research results with dl1520 (Onyx-015), a replication-selective adenovirus for the treatment of cancer: What have we learned?

Gene Therapy

Volumn 8, Issue 2, 2001, Pages 89-98

  Kirn, D ^a  

^a IMPERIAL COLLEGE SCHOOL OF MEDICINE   (United Kingdom)

Author keywords

Adenovirus; Cancer; Clinical trials; dl1520; Oncolytic

Indexed keywords

ALANINE AMINOTRANSFERASE; ANTINEOPLASTIC AGENT; ASPARTATE AMINOTRANSFERASE; BETA GALACTOSIDASE; BINDING PROTEIN; CISPLATIN; CYTOKINE; FLUOROURACIL; FOLINIC ACID; GEMCITABINE; INTEGRIN; INTERLEUKIN 1; INTERLEUKIN 10; INTERLEUKIN 6; MESSENGER RNA; NEUTRALIZING ANTIBODY; ONCOLYTIC VIRUS; PACLITAXEL; PROTEIN P53; RECOMBINANT DNA; THYMIDINE KINASE; TUMOR NECROSIS FACTOR ALPHA; VIRUS DNA; VIRUS ENZYME; VIRUS RECEPTOR;

ADENOVIRUS; ANTINEOPLASTIC ACTIVITY; CANCER; CANCER CHEMOTHERAPY; CANCER PATIENT; CANCER THERAPY; CLINICAL RESEARCH; CONTROLLED STUDY; DRUG ADMINISTRATION ROUTE; GENE DELETION; GENE THERAPY; GENETIC ENGINEERING; HUMAN; NONHUMAN; PARTICLE SIZE; PRIORITY JOURNAL; REVIEW; TUMOR REGRESSION; VIRAL GENETICS; VIRUS REPLICATION; VIRUS STRAIN;

ADENOVIRIDAE; CLINICAL TRIALS; GENE THERAPY; GENETIC VECTORS; HUMANS; NEOPLASMS; VIRUS REPLICATION;

ADENOVIRIDAE; DNA VIRUSES; ONYX;

EID: 0035134629     PISSN: 09697128     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.gt.3301377     Document Type: Review

References (65)

1. Clinical phase I experience with INGN 201 (Ad-p53) in non-small cell lung cancer and head and neck cancer
2. Three phase II trials of intratumoral injection with a replication-deficient adenovirus carrying the p53 gene (AdCMV-p53) in patients with recurrent/refractory head and neck cancer
3. Replication-selective micro-organisms: Fighting cancer with targeted germ warfare
4. Replication-selective adenoviruses as oncolytic agents
5. Tumor-targeted Salmonella as a novel anticancer vector
6. Intravenous administration of ONYX-015, a selectively-replicating adenovirus, induces antitumoral efficacy
7. Selectively-replicating viruses as therapeutic agents against cancer
8. Studies on the use of viruses in the treatment of carcinoma of the cervix
9. Viruses in the treatment of cancer
10. Treatment of human cancer with mumps virus
11. Experimental therapy of human glioma by means of a genetically engineered virus mutant
12. Treatment of malignant gliomas using ganciclovir-hypersensitive, ribonucleotide reductase-deficient herpes simplex viral mutant
13. Attenuated multi-mutated herpes simplex virus-1 for the treatment of malignant gliomas
14. An adenovirus mutant that replicates selectively in p53-deficient human tumor cells
15. ONYX-015, an E1B gene-attenuated adenovirus, causes tumor-specific cytolysis and antitumoral efficacy that can be augmented by standard chemotherapeutic agents
16. Complete regression of human fibrosarcoma xenografts after local Newcastle disease virus therapy
17. Parvovirus H-1 inhibits growth of short-term tumor-derived but not normal mammary tissue cultures
18. Reovirus therapy of tumors with activated ras pathway
19. Poxvirus vectors: Orphaned and underappreciated
20. Intergeneric poliovirus recombinants for the treatment of malignant glioma
21. Exploiting tumor-specific defects in the interferon pathway with a previously unknown oncolytic virus
22. Adenovirus proteins that subvert host defenses
23. The role of human adenovirus early region 3 proteins (gp19K, 10.4K, 14.5K, and 14.7K) in a murine pneumonia model
24. Prostate attenuated replication competent adenovirus (ARCA) CN706: A selective cytotoxic for prostate-specific antigen-positive prostate cancer cells
25. Efficacy of a replication-competent adenovirus (ONYX-015) following intratumoral injection: Intratumoral spread and distribution effects
26. Experimental therapy of human glioma by means of a genetically engineered virus mutant
27. Attenuated multi-mutated herpes simplex virus-1 for the treatment of malignant gliomas
28. p53 alterations in recurrent squamous cell cancer of the head and neck refractory to radio-therapy
29. The state of the p53 and retinoblastoma genes in human cervical carcinoma cell lines
30. p53 mutations in human cancers
31. p53-independent and -dependent requirements for E1B-55kD in adenovirus type 5 replication
32. Hepatic arterial infusion of a replication-selective adenovirus, Onyx-015: A phase I/II clinical trial
33. Hepatic arterial infusion of chemotherapy following resection of hepatic metastases from colorectal cancer
34. A phase I study of Onyx-015, an E1B attenuated adenovirus, administered intratumorally to patients with recurrent head and neck cancer
35. A phase I study of multiple direct injections of ONYX-015 adenovirus under endoscopic ultrasound guidance
36. Endoscopic ultrasound-guided intratumoral injection of pancreatic carcinomas with a replication-selective adenovirus: A phase I/II clinical trial
37. A phase II trial of ONYX-015, a selectively-replicating adenovirus, in combination with cisplatin and 5-fluorouracil in patients with recurrent head and neck cancer
38. A phase I trial of an E1B-55kD gene-deleted adenovirus administered by intraperitoneal injection into patients with advanced, refractory ovarian carcinoma
39. A phase I trial of intravenous administration with a replication-selective adenovirus, dl 1520
40. A controlled trial of Onyx-015, an E1B gene-deleted adenovirus, in combination with chemotherapy in patients with recurrent head and neck cancer
41. A phase I/II trial of ONYX-015 administered by hepatic artery infusion to patients with colorectal carcinoma
42. A phase II trial of intratumoral injection with an E1B-deleted adenovirus, ONYX-015, in patients with recurrent, refractory head and neck cancer
43. ONYX-015, an E1B gene-attenuated adenovirus, causes tumor-specific cytolysis and antitumoral efficacy that can be augmented by standard chemotherapeutic agents
44. A controlled trial of intratumoral ONYX-015, a selectively-replicating adenovirus, in combination with cisplatin and 5-fluorouracil in patients with recurrent head and neck cancer
45. p53 status does not determine outcome of E1B 55-kilodalton mutant adenovirus lytic infection
46. Replication of ONYX-015, a potential anticancer adenovirus, is independent of p53 status in tumor cells
47. Blockage by adenovirus E4orf6 of transcriptional activation by the p53 tumor suppressor
48. Adenovirus E1B oncoprotein tethers a transcriptional repression domain to p53
49. The early region 1B 55-kilodalton oncoprotein of adenovirus relieves growth restrictions imposed on viral replication by the cell cycle
50. An E1A mutant adenovirus with potent and selective systemic antitumoral efficacy
51. Adenovirus proteins from both E1B reading frames are required for transformation of rodent cells by viral infection and DNA transfection
52. Nuclear export of the E1B 55-kDa and E4 34-kDa adenoviral oncoproteins mediated by a rev-like signal sequence
53. Regulation of TNF-mediated cell death and inflammation by human adenoviruses
54. Adenovirus E1A CR2 mutants as selectively-replicating agents for cancer
55. A mutant oncolytic adenovirus targeting the Rb pathway produces anti-glioma effect in vivo
56. Replicating adenoviral gene therapy
57. A novel three-pronged approach to kill cancer cells selectively: Concomitant viral, double suicide gene, and radiotherapy
58. Therapy of colon cancer with oncolytic adenovirus is enhanced by the addition of herpes simplex virus-thymidine kinase
59. Long-term survival of rats harboring brain neoplasms treated with ganciclovir and a herpes simplex virus vector that retains an intact thymidine kinase gene
60. Identification of a conserved receptor-binding site on the fiber proteins of CAR-recognizing adenoviridae
61. In situ cytokine gene transfection using vaccinia virus vectors
62. Lipid A mutant salmonella with suppressed virulence and TNF-alpha induction retain tumor-targeting in vivo
63. Selective replication and oncolysis in p53 mutant tumors with Onyx-015, an E1B-55kD gene-deleted adenovirus, in patients with head and neck cancer
64. Combination therapy with a replication-selective adenovirus and cisplatin chemotherapy; dependence on sequencing but independence from p53 gene status or route of administration
65. Loss of p14ARF in tumor cells facilitates replication of the adenovirus mutant dl1520 (Onyx-015)